Physician profile
Stephen Lucas
NPI 1346235074
$3,781.75
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $1,067 · 2021: $729 · 2022: $677 · 2023: $522 · 2024: $15.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,126.27 | 2019-2023 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.04 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $374.35 | 2019-2023 | Breztri, Tezspire |
| Octapharma USA, INC. | $258.61 | 2020 | |
| Grifols USA, LLC | $186.63 | 2019-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $167.71 | 2019-2023 | Yupelri |
| Insmed, INC. | $143.58 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $136.25 | 2020-2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $122.71 | 2021-2023 | Uptravi |
| Genzyme Corporation | $108.72 | 2019-2021 | |
| Harmony Biosciences LLC | $108.46 | 2022-2023 | Wakix |
| United Therapeutics Corporation | $105.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $68.54 | 2021 | |
| Genentech USA, INC. | $64.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.86 | 2022-2023 | Glassia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $43.56 | 2019 | |
| Baxter Healthcare | $39.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $38.01 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.38 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $32.12 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $30.90 | 2020-2021 | |
| Optinose US, INC. | $24.35 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.82 | 2023 | Purified Cortrophin Gel |
| Circassia INC. | $19.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.48 | 2023 | |
| Pfizer INC. | $15.29 | 2024 | |
| Abbvie INC. | $14.74 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.94 | 2021 | |
| Daiichi Sankyo INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.